Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Myelosuppression with capecitabine

Ixabepilone, a microtubule stabilizing agent, is indicated as monotherapy or in combination with capecitabine in MBC patients who have previously received an anthracycline and a taxane. Response rates and time to progression were increased with combination therapy as compared with capecitabine alone. Adverse effects include myelosuppression, peripheral neuropathy, and myalgias/arthralgias. [Pg.700]

Although not a taxane, ixabepilone is a novel microtubule inhibitor that was recently approved for metastatic breast cancer in combination with the oral fluoropyrimidine capecitabine or as monotherapy. It is a semisynthetic analog of epothilone B, and is active in the M phase of the cell cycle. This agent binds directly to 6-tubulin subunits on microtubules, leading to inhibition of normal microtubule dynamics. Of note, this agent continues to have activity in drug-resistant tumors that overexpress P-glycoprotein or tubulin mutations. The main adverse effects include myelosuppression, hypersensitivity reactions, and neurotoxicity in the form of peripheral sensory neuropathy. [Pg.1177]


See other pages where Myelosuppression with capecitabine is mentioned: [Pg.1319]    [Pg.34]    [Pg.1173]    [Pg.1294]    [Pg.145]    [Pg.2356]    [Pg.2356]    [Pg.2356]    [Pg.2357]    [Pg.876]   
See also in sourсe #XX -- [ Pg.1285 ]




SEARCH



Capecitabin

Myelosuppression

© 2024 chempedia.info